A, Gastroenterologists (n = 451). B, Endoscopy nurses (n = 460). The color-coded panel shows the key for the specific preference reasons. The letters represent a key for the specific reasons, and the numbers given represent percentages.
Agrawal D, Rockey DC. Propofol for Screening Colonoscopy in Low-Risk PatientsAre We Paying Too Much?. JAMA Intern Med. 2013;173(19):1836-1838. doi:10.1001/jamainternmed.2013.8417
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Use of propofol for sedation for screening colonoscopy in low-risk patients has increased markedly recently.1,2 In the United States, propofol is administered only by an anesthesiology provider, which can substantially increase cost (typically $600-$2000). Given the number of screening colonoscopies performed every year, additional health care costs associated with this practice are substantial. The advantages of propofol over standard moderate sedation using a narcotic and/or benzodiazepine include quicker onset of action, a shorter half-life, and deeper level of sedation. However, evidence supporting the potential benefits of propofol is limited.3 For screening colonoscopy in low-risk patients, the question thus becomes, what is propofol worth? For a patient who has never had a colonoscopy, this is a very difficult question to answer, since it is challenging to associate a dollar amount to comfort without knowledge of the likely degree of discomfort. Hence, we approached this question by asking those who are most familiar with colonoscopy and sedation medications—namely gastroenterologists and endoscopy nurses.
We validated a 3-question questionnaire by interviewing and asking 20 endoscopy physicians and nurses from 3 different endoscopy units to answer questions in an open-ended manner; responses were used to construct the final questionnaire, which was then reviewed by additional gastroenterologists. The questions were as follows:
If you were to have screening colonoscopy, what sedation would you prefer?
Midazolam-fentanyl (moderate sedation).
Propofol (deep sedation).
If you prefer propofol, how much extra would you be willing to pay out of pocket?
More than $500
I prefer propofol because (check all that apply):
I do not want to feel anything.
My recovery time will be faster.
I want to be taken care of by an anesthesiologist/certified registered nurse anesthetist.
The questionnaire was placed on SurveyMonkey.com and the link emailed to specific gastroenterology division directors asking them to distribute it to their faculty. Responses were also obtained by direct distribution and/or interview at the Digestive Diseases Week (the major national gastroenterology meeting). To obtain nurse responses, we attended 6 Society of Gastroenterology Nurses Association meetings and distributed paper questionnaires at the beginning of random oral sessions; responses were collected immediately after the session.
Responses were received from 451 gastroenterologists and 460 nurses. The response rate for nurses, calculated as number of questionnaires with responses divided by number of questionnaires distributed, was 84%. For the gastroenterologists, the response rate was 87% for directly distributed questionnaires and 23% by web (SurveyMonkey.com). Gastroenterologists and nurses preferred propofol vs moderate sedation, but most were willing to pay less than $100 (Table). Interestingly, many gastroenterologists and nurses preferred unsedated colonoscopy. When propofol was preferred, reasons given by gastroenterologists and nurses (respectively) were as follows: don’t want to feel anything (78% and 91%), faster recovery time (89% and 69%), and prefer that anesthesiology provider administer anesthesia (11% and 35%). As expected, most individuals had more than 1 reason for desiring propofol compared with moderate sedation (Figure).
Deep sedation with propofol was preferred by most of gastroenterologists and endoscopy nurses surveyed. However, most were unwilling to pay more than $200, far less than is currently charged to patients. Thus, why are gastroenterologists performing so many colonoscopies with propofol when they value it at less than current cost? The answer is undoubtedly complex. First, since recovery is faster after propofol (by approximately 21 minutes3), it may increase endoscopy unit efficiency. Notably, for the patient, earlier discharge offers only a limited advantage since discharge instructions are the same for propofol and standard moderate sedation. Some have argued that pain may be less with propofol; however, a recent meta-analysis demonstrated that pain scores were no different than with moderate sedation.3 Finally, depending on the business model and anesthesiologist contracting, professional and facility fees associated with propofol can be quite financially lucrative.5
Insurers often do not cover the entire cost of propofol administration, and patients often end up paying considerable (>$1000) amounts for this service.4,6 Thus, it behooves us to ask, is it fair for a gastroenterologist to ask a patient to pay more for a service than what she or he is willing to pay? Would patients react differently if they were told that many gastroenterologists prefer moderate sedation or that 70% would not pay more than $100 for propofol? Perhaps information such as this should be part of the informed consent process. Furthermore, even when patients may not have to pay extra, is the additional expense to the health care system justifiable? As one respondent physician stated, “I will fly first class if I don’t have to pay for it.” It seems that many are flying first class when we cannot really afford it.
Although these data demonstrate that endoscopy nurses and physicians prefer propofol, it seems that there is a large difference between actual cost and perceived value.
Corresponding Author: Don C. Rockey, MD, Department of Internal Medicine, Medical University of South Carolina, 96 Jonathan Lucas St, Ste 803, Charleston, SC 29425 (email@example.com).
Author Contributions: Both authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Both authors.
Acquisition of data: Agrawal.
Analysis and interpretation of data: Both authors.
Drafting of the manuscript: Both authors.
Critical revision of the manuscript for important intellectual content: Both authors.
Statistical analysis: Both authors.
Administrative, technical, and material support: Both authors.
Study supervision: Rockey.
Published Online: July 15, 2013. doi:10.1001/jamainternmed.2013.8417.
Conflict of Interest Disclosures: None reported.
Additional Contributions: We thank all of those who filled out questionnaires.